SOURCE: PharmaCom BioVet, Inc.

November 18, 2008 17:26 ET

PharmaCom BioVet, Inc. Announces Cancer Care Centers to Incorporate Significant Benefits of Lymphoma Blood Tests for Canine Cancer Treatments

RALEIGH, NC--(Marketwire - November 18, 2008) - PharmaCom BioVet, Inc. (PINKSHEETS: PHMB). PharmaCom BioVet, Inc. is pleased to announce the incorporation of PetScreen LTD into their companion animal treatment centers and the benefits of PetScreen, LTD's Lymphoma Blood Testing in the treatment of canine cancer treatments.

PharmaCom BioVet, Inc. President and CEO, Gary Berthold has confirmed plans to promote and incorporate current Lymphoma Blood Testing programs developed by PetScreen LTD of Nottingham, UK into its new canine cancer treatments centers. In a recent letter from PetScreen LTD's CEO, Dr. Kevin Slater, the collaboration between the two companies is seen as an important step forward in improving cancer diagnosis and treatment for companion animals. "Lymphoma is one of the most common forms of cancer in dogs and accounts for a significant percentage of cancer deaths," Berthold noted. "The Canine Lymphoma Blood Test procedure pioneered by PetScreen will provide our treatment centers, and veterinarians everywhere, with a very simple means of testing for the disease."

"The benefits are wide ranging and will aid in the screening, diagnosis and monitoring of lymphoma treatments programs," Berthold continued. "This process is highly valuable in tracking the efficacy of various levels of treatment as well as the overall results from radio pharmaceutical usage. Of equal importance is its ability to provide vital information once a patient's cancer has gone into remission. It will allow us to better determine how the treatment worked and, consequently, how to replicate those results," he added.

"Our recent collaboration with PetScreen LTD further enables us to provide effective, state-of-the-art canine cancer treatment programs within our treatment centers," offered Berthold. "Our goal is to help lead the way towards the highest achievements possible in cancer care for companion animals. One of the key factors in attaining this goal is the formation of synergistic relationships with professionals around the country and the world. With each collaboration, we are working to assemble the best minds in the field of cancer research and veterinary oncology. Combined with leading edge technologies and procedures, such as Lymphoma Blood Testing, our hope is to accelerate the progress towards optimum treatment results and an eventual cure," he concluded.

PetScreen LTD, founded by Dr. Slater and Board Chairman, Professor Graeme Radcliffe, was established to provide veterinarians with improved testing methodologies in order to help them make better diagnostic and treatment decisions for companion animals with cancer. The company features a comprehensive range of services and a growing cooperative network of industry professionals.

PharmaCom BioVet, Inc. is the inspiration of Gary and Sharon Berthold of Raleigh, NC. Avid Siberian Husky breeders and life-long dog lovers, the Berthold's were driven to establish the company following the loss of two of their most precious Siberian Huskies to cancer. While researching medical remedies, they discovered a growing nationwide demand for canine cancer care along with an astonishing lack of effective treatment options. To address these realities, they formed PharmaCom BioVet, Inc. to establish canine cancer treatment centers around the country. These facilities will link the brightest veterinary leaders with the latest oncology technologies to offer the most advanced cancer treatment programs available.

About PharmaCom BioVet, Inc.:

PharmaCom BioVet, Inc. is dedicated to advancing the veterinary care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the country. The purpose of these centers is to help prolong the quality of life for companion animals with cancer and pursue the potential for complete cure. These centers will also operate under the philosophy of providing a compassionate care environment for both companion animal patients and their owners. For more information, please visit our website

About PetScreen, LTD:

PetScreen LTD. is headquartered and operates laboratories in Nottingham, England. Its purpose is to develop and apply new technologies directed towards improving cancer diagnosis and treatment in dogs and other companion animals. Their facilities offer services such as Canine Lymphoma Blood Tests, which provide veterinarians with a simple means of screening, diagnosis and monitoring treatment of dogs with lymphoma. Their DCA program (Directed Chemotherapy Assay) helps in determining the most effective chemotherapy treatment for each individual canine cancer patient. From their UK location, they have developed a network of national and international collaborators to provide services and support to the veterinary cancer patient. For more information, please visit the website at

About IsoTherapeutics Group, LLC:

The mission of IsoTherapeutics Group, LLC is to develop novel diagnostic and therapeutic agents for the treatment of severe diseases. ITG both develops their own technologies as well as partners with other companies to help develop pharmaceuticals. Of special interest are radiopharmaceuticals for oncology. In house expertise includes synthetic organic chemistry, chelation chemistry, radiochemistry, diagnostic and therapeutic isotopes, conjugation chemistry, pharmacokinetics, and small animal research models. For more information, please visit our website


"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contact Information